Serena Williams, Ro, and the $8 Million GLP-1 Super Bowl bet
Industry Buzz
Instead of mentioning [GLP-1s] in hushed tones—as if these drugs are somehow controversial or illicit—patients are now coming right out and saying they want to try them because their favorite influencers and personalities have mentioned them
—Roberto Valledor, MD, board-certified family medicine physician
Weight loss is no longer the endpoint—risk reduction is. GLP-1 agonists have normalized the idea that obesity treatment belongs alongside lipid management and cardiovascular prevention.
—Alpana Mohta, MD, DNB, FEADV, FIADVL, IFAAD
For most of the last decade, Big Pharma’s Super Bowl presence felt defensive: brand awareness, soft lifestyle framing, and avoidance of anything resembling a clinical claim. That posture changed this year, and all eyes will be watching as GLP-1s explode the ad lineup.
Super Bowl ad inventory for 2026 averaged $8 million per 30-second spot, with premium placements exceeding $10 million.[] Despite rising costs, health companies did not pull back.
With obesity pharmacotherapy, cardio-renal protection, and metabolic disease now mainstays in standard-of-care conversations, pharma is now treating the Super Bowl as a trust-building channel.
The 'Healthier on Ro' campaign
Ro’s first Super Bowl appearance makes the shift explicit. The “Healthier on Ro” campaign, led by Serena Williams, avoids aspirational weight imagery.[] Instead, it centers lab markers and cardiovascular risk. In a January 2026 interview, Williams said she has lowered her cholesterol by 30%, lost 34 pounds, and lowered her lifetime risk of heart disease by a relative 70% since using GLP-1 medication with Ro. She said, “I feel healthier. I feel lighter. I feel great. It's a really good feeling … Something I've seen improvement on recently were just my numbers."
Ro was not alone. Boehringer Ingelheim also aired a Super Bowl ad promoting kidney health awareness.[] The campaign focused on early screening for chronic kidney disease using urine albumin-creatinine ratio testing in patients with diabetes or hypertension. The creative hook involved celebrities, but the call to action was clinical and specific: test earlier, identify damage sooner.
Why these campaigns matter
This framing matters for clinicians because it mirrors how obesity medicine has evolved within practice.
Weight loss is no longer the endpoint—risk reduction is. GLP-1 agonists have normalized the idea that obesity treatment belongs alongside lipid management and cardiovascular prevention.
—Alpana Mohta, MD, DNB, FEADV, FIADVL, IFAAD
Physicians are describing such campaigns as an attempt to strip GLP-1 therapy of stigma and reposition it as medical care rather than a shortcut. Roberto Valledor, MD, a board-certified family medicine physician who serves as a collaborating physician for Mochi Health’s telemedicine platform, says, “Celebrity endorsements have certainly impacted my patient interactions. Instead of mentioning diet medications in hushed tones—as if these drugs are somehow controversial or illicit—patients are now coming right out and saying they want to try them because their favorite influencers and personalities have mentioned them.”
Vivek Gupta, MD, MPH, a board-certified internal medicine physician and board-certified obesity medicine specialist, says, “In the last few years, I’ve seen many patients who previously would never have considered an injectable therapy become much more open to it because of figures like Oprah and Vanessa Williams.”
Cardiology guidance has also shifted.
In 2025, the American College of Cardiology issued updated recommendations supporting earlier use of obesity pharmacotherapy when cardiometabolic risk is present. The statement rejected the long-standing requirement that patients “try and fail” lifestyle intervention before medication initiation.[]
That shift helps explain the need for public awareness of anti-obesity medications. As science moved these drugs into earlier, mainstream care, public education became essential for access and adherence.
Weight loss is no longer the destination—risk reduction is. GLP-1 agonists have shifted the paradigm, placing obesity treatment exactly where it belongs: alongside lipid management and cardiovascular health. The goal isn't just a lower number on the scale; it's longevity.
However, increased visibility has also changed expectations inside the exam room. Dr. Valledor warns, “At the same time, I do have to temper expectations for some who believe they’re going to have the results they saw in an Instagram ad. Generally, I think it’s helpful for the public to view obesity as something that’s treatable with medications instead of just trying to lose a few pounds for a ‘beach body.’”
Many patients with high BMI now arrive asking for a specific drug, making the early part of the visit less about awareness and more about appropriateness. GLP-1 therapy fits some patients well, while others require a different approach or more groundwork before medication is considered.
According to Dr. Gupta, “From a clinician's perspective, BMI alone is an incomplete tool. When deciding whether GLP-1 therapy is appropriate, we look at a broad set of clinical and personal factors, including HbA1C and glucose trends; lipid panel and cardiometabolic risk; liver enzymes and fatty liver disease risk; comorbidities like sleep apnea, arthritis, and mobility limitations; alcohol use patterns; weight trajectory; patient goals; readiness; and support systems.”
Read Next: Wins and losses: Mapping the GLP-1 receptor’s path